BCBS to launch retiree health insurance exchange
April 27th 2015Blue Cross and Blue Shield will launch a health insurance exchange this summer that will support employers’ efforts to help retirees transition from group health benefits to individual Medicare coverage that starts Jan. 1, 2016.
Read More
New data: Hospital readmission among NVAF hospitalized patients treated with new oral anticoagulants
April 24th 2015Data from a real-world analysis provided an early view of hospital readmissions among hospitalized nonvalvular atrial fibrillation (NVAF) patients treated with new oral anticoagulants (NOACs).
Read More
Statins cost-effective in elderly patients: Study
April 23rd 2015Statins could be a cost-effective tool for preventing heart attacks and other cardiovascular incidents in adults over aged 75 years, but the benefits would need to be weighed against potential side effects, a study in the Annals of Internal Medicine.
Read More
Study finds liposomal bupivacaine improves patient, cost outcomes after knee replacement
April 23rd 2015Use of bupivacaine liposome injectable suspension (Exparel) was associated with im-proved clinical outcomes and a favorable cost savings per patient compared to the standard of care, according to data presented at the 27th annual meeting and expo of the Academy of Managed Care Pharmacy in San Diego.
Read More
Teva’s Mylan bid set to shake up industry
April 22nd 2015Teva Pharmaceutical’s unsolicited $40 billion offer to acquire Mylan N.V. is expected to shake up the pharmaceutical industry, especially in the areas of generic and specialty drugs. A Teva acquisition of Mylan would be the biggest health care deal of the year so far and the largest acquisition ever proposed by an Israeli company, according to S.&P. Capital IQ, The New York Times reported.
Read More
Children with cerebral palsy, epilepsy need flu vaccine but don’t always get it
April 21st 2015Children who have neurological disorders such as cerebral palsy or epilepsy are no more likely to be vaccinated against influenza than children without these conditions, despite the increased risk for complications from flu these children experience, according to a study published online April 9 in Vaccine. Moreover, healthcare providers may not be familiar with the increased risk among these patients to effectively recommend influenza vaccine.
Read More
Drop in opioid Rx, overdoses linked to pharmacy changes
April 21st 2015The introduction of abuse-deterrent OxyContin, couple with the removal of propoxyphene from the US prescription marketplace may have played a role in decreasing opioid prescribing and overdoses, according to a study published in JAMA Internal Medicine.
Read More
Be vigilant of counterfeit version of Botox found in United States
April 20th 2015A counterfeit version of onabotulinumtoxinA (Botox) was found in the United States and may have been sold to doctors’ offices and medical clinics nationwide. The version is considered unsafe and should not be used.
Read More
FDA approves Corlanor to treat heart failure
April 17th 2015FDA has approved ivabradine (Corlanor, Amgen) to reduce hospitalization due to worsening heart failure. Corlanor is an antianginal agent approved for use in patients who have chronic heart failure caused by the lower-left part of the heart not contracting well.
Read More
FDA approves changes to hep C drug label to include new warnings
April 17th 2015FDA has approved changes to the hepatitis C antiviral simeprevir (Olysio, Janssen) label to include new warnings about serious symptomatic bradycardia-slowing of the heart rate-when co-administered with antiarrhythmic drug amiodarone and antiviral sofosbuvir (Solvaldi, Gilead).
Read More
Waldenstrom’s drug shows sustained benefit at 2 years
April 15th 2015Ibrutinib, a newly approved drug for Waldenstrom’s Macroglobulinemia, a rare form of lymphoma, continued to control the rare blood cancer, with 95% of patients surviving for 2 years, according to a new study, published in The New England Journal of Medicine.
Read More
Study: Drug costs for hereditary angioedema tripled in 2 years
April 15th 2015Patients with hereditary angioedema (HAE) are accruing specialty drug treatment costs of more than $300,000 annually on average, according to a study presented at the Academy of Managed Care Pharmacy (AMCP) 27th Annual Meeting and Expo, in San Diego.
Read More
[BLOG]: Clinical pharmacogenomics: Meeting the needs of the community through a dedicated clinic
April 15th 2015BLOG: Pharmacogenomics is the study of how DNA differences affect response to medications. This can explain why similar patients have different reactions to the same medication even if they receive the same dosage. The pharmacogenomics clinic at NorthShore is the first step toward a larger implementation.
Read More
New cystic fibrosis drugs may significantly increase pharmacy benefit costs
April 15th 2015New cystic fibrosis treatments, that target the gene mutations causing the disease, will significantly increase healthcare costs, according to a study presented at the Academy of Managed Care Pharmacy (AMCP) 27th Annual Meeting and Expo, in San Diego.
Read More
Study: Reduce long-term care use among patients with Parkinson’s disease psychosis
April 14th 2015Reducing long-term care utilization among patients with Parkinson’s disease psychosis (PDP) may lower overall economic burden, according to data presented at the American Managed Care Pharmacy 27th Annual Meeting & Expo in San Diego.
Read More
Study: Babies exposed to narcotic pain relievers more likely to experience drug withdrawal syndrome
April 14th 2015Pregnant women are commonly being prescribed opioids - narcotic pain relievers such as hydrocodone - which results in an increased likelihood of neonatal abstinence syndrome (NAS), a drug withdrawal syndrome that opioid-related infants experience shortly after birth, according to a study in Pediatrics.
Read More
Cancer drug prices not linked to survival rates
April 10th 2015The pricing of oncology drugs is not necessarily based on their novelty or effectiveness, according to a new JAMA Oncology study. Instead, researchers found, “current pricing models are not rational but simply reflect what the market will bear.”
Read More